Patents by Inventor Olivier Potterat
Olivier Potterat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11896707Abstract: The present invention relates to the use of plant extracts from the genus Daphne for the cosmetic treatment of the skin and to cosmetic preparations which comprise extracts of Daphne giraldii and/or Daphne gnidium or other members of the genus Daphne containing daphnetoxin and/or other daphnane diterpenoids for skin treatment. The plant extracts and cosmetic preparations are particularly useful for stimulation of the lymphatic system.Type: GrantFiled: December 10, 2019Date of Patent: February 13, 2024Assignees: ETH Zurich, Universität BaselInventors: Michael Detmar, Epameinondas Gousopoulos, Olivier Potterat, Jihye Kim, Adriana Sliwa-Primorac, Antonia Elisabeth Schantl, Maria Teresa Faleschini, Matthias Hamburger
-
Publication number: 20220257501Abstract: The present invention relates to the use of a combination of plant extracts from the genera Salvia, Artemisia, Echinacea, and optionally further plant extracts, for the cosmetic treatment of the skin. The invention further relates to cosmetic preparations which comprise such combination of plant extracts. These plant extracts and cosmetic preparations are particularly useful for stimulation of the lymphatic system, including rejuvenation, anti-ageing, detoxification and increased firmness of the skin, for puffy-eye treatment and/or for anti-swelling effects.Type: ApplicationFiled: July 13, 2020Publication date: August 18, 2022Applicants: ETH Zurich, Universität BaselInventors: Michael Detmar, Epameinondas Gousopoulos, Matthias Hamburger, Olivier Potterat, Jihye Kim, Antonia Elisabeth Schantl
-
Publication number: 20220175696Abstract: The present invention refers to lipophilic extracts of members of the Iridaceae family, such as Iris germanica and/or Iris pallida, that have been found to promote lymphatic function. These extracts are suitable for the treatment of skin inflammation, rheumatoid arthritis, impaired wound healing, chronic inflammatory diseases, chronic airway inflammation, inflammatory bowel disease, rosacea, primary and/or secondary lymphedemas. The most active components were found to be the iridals.Type: ApplicationFiled: February 24, 2022Publication date: June 9, 2022Inventors: Michael Detmar, Matthias Hamburger, Olivier Potterat, Adriana Sliwa-Primorac
-
Publication number: 20220054396Abstract: The present invention relates to the use of plant extracts from the genus Daphne for the cosmetic treatment of the skin and to cosmetic preparations which comprise extracts of Daphne giraldii and/or Daphne gnidium or other members of the genus Daphne containing daphnetoxin and/or other daphnane diterpenoids for skin treatment. The plant extracts and cosmetic preparations are particularly useful for stimulation of the lymphatic system.Type: ApplicationFiled: December 10, 2019Publication date: February 24, 2022Applicants: ETH Zurich, Universität BaselInventors: Michael Detmar, Epameinondas Gousopoulos, Olivier Potterat, Jihye Kim, Adriana Sliwa-Promorac, Antonia Elisabeth Schantl, Maria Teresa Faleschini, Matthias Hamburger
-
Patent number: 10869474Abstract: The present invention relates to the use of a composition as a fungicide, wherein said composition comprises at least one compound of formula (I) or formula (II) wherein wherein R2, R3, R4, R5, R6 and R7 are independently of each other H, OH or OCH3.Type: GrantFiled: June 20, 2017Date of Patent: December 22, 2020Assignees: UNIVERSITÄT BASEL, FORSCHUNGSINSTITUT FÜR BIOLOGISCHEN LANDBAU (FIBL)Inventors: Matthias Hamburger, Olivier Potterat, Justine Ramseyer, Hans-Jakob Schärer, Barbara Thürig, Lucius Tamm, Thomas Oberhänsli
-
Publication number: 20200147004Abstract: The present invention refers to lipophilic extracts of members of the Iridaceae family, such as Iris germanica and/or Iris pallida, that have been found to promote lymphatic function. These extracts are suitable for the treatment of skin inflammation, rheumatoid arthritis, impaired wound healing, chronic inflammatory diseases, chronic airway inflammation, inflammatory bowel disease, rosacea, primary and/or secondary lymphedemas. The most active components were found to be the iridals.Type: ApplicationFiled: January 17, 2020Publication date: May 14, 2020Applicants: UNIVERSITAET BASEL, ETH ZUERICHInventors: Michael Detmar, Matthias Hamburger, Olivier Potterat, Adriana Sliwa-Primorac
-
Publication number: 20190200609Abstract: The present invention relates to the use of a composition as a fungicide, wherein said composition comprises at least one compound of formula (I) or formula (II), wherein R1=formula (IV) or Formula (V), wherein R2, R3, R4; R5, R6 and R7 are independently of each other H, OH or OCH3.Type: ApplicationFiled: June 20, 2017Publication date: July 4, 2019Inventors: Matthias HAMBURGER, Olivier POTTERAT, Justine RAMSEYER, Hans-Jakob SCHÄRER, Barbara THÜRIG, Lucius TAMM, Thomas OBERHÄNSLI
-
Publication number: 20160367499Abstract: The present invention refers to lipophilic extracts of members of the Iridaceae family, such as Iris germanica and/or Iris pallida, that have been found to promote lymphatic function. These extracts are suitable for the treatment of skin inflammation, rheumatoid arthritis, impaired wound healing, chronic inflammatory diseases, chronic airway inflammation, inflammatory bowel disease, rosacea, primary and/or secondary lymphedemas. The most active components were found to be the iridals.Type: ApplicationFiled: November 17, 2015Publication date: December 22, 2016Applicants: UNIVERSITAET BASEL, ETH ZUERICHInventors: Michael Detmar, Matthias Hamburger, Olivier Potterat, Adriana Sliwa-Primorac
-
Patent number: 7101848Abstract: The invention relates to a bicyclic oligopeptide or ester thereof having the capability to inhibit the glucagon receptor, comprised of: (a) a first cyclic group, which comprises at least one cysteine group and is formed by an amide bonding of the N-terminal amino acid with the second carboxylate group of a diacid amino acid, and (b) a second cyclic group which is formed by an amide bonding of an amino acid with the ?-carboxylate group of said diacid amino acid, and by a disulfide bonding of the C-terminal cysteine and a cysteine group within the first cyclic group (a); and to the use of such bicyclic oligopeptides for the preparation of a medicament for the treatment or prevention of diseases, in which glucagon receptors are involved.Type: GrantFiled: July 17, 2003Date of Patent: September 5, 2006Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Olivier Potterat, Ruediger Streicher, Klaus Wagner, Till Maurer, Juergen Mack, Stefan Peters
-
Publication number: 20040072736Abstract: The invention relates to a bicyclic oligopeptide or ester thereof having the capability to inhibit the glucagon receptor, comprised of:Type: ApplicationFiled: July 17, 2003Publication date: April 15, 2004Applicant: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Olivier Potterat, Ruediger Streicher, Klaus Wagner, Till Maurer, Juergen Mack, Stefan Peters